-
Mashup Score: 0CHMP Recommends First-Line Pembrolizumab Plus Chemotherapy for PD-L1+, HER2– Advanced Gastric/GEJ Adenocarcinoma - 6 month(s) ago
The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of adult patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0CHMP Recommends First-Line Pembrolizumab Plus Chemotherapy for PD-L1+, HER2– Advanced Gastric/GEJ Adenocarcinoma - 7 month(s) ago
The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of adult patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CHMP Recommends First-Line Pembrolizumab Plus Chemotherapy for PD-L1+, HER2– Advanced Gastric/GEJ Adenocarcinoma #esocsm #oncology https://t.co/ujxaDfE0ia
-
-
Mashup Score: 4Addition of First-Line Regorafenib to Nivolumab and Chemotherapy in Metastatic Esophageal Cancer - The ASCO Post - 7 month(s) ago
In a single-institution phase II study reported in The Lancet Oncology, Cytryn et al found that the combination of regorafenib, nivolumab, and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) showed activity as a first-line treatment regimen for patients with HER2-negative metastatic esophagogastric adenocarcinoma. In the investigator-initiated trial, 39 patients enrolled between February 2021 and May 2022 at Memorial Sloan Kettering Cancer Center received FOLFOX (fluorouracil at 400 mg/m² bolus
Source: ascopost.comCategories: Latest Headlines, Oncologists2Tweet-
RT @ASCOPost: Novel Triplet for Metastatic Esophageal Cancer: Study Results https://t.co/LaK7kC3Ip0 #esocsm #esophagealcancer #oncology
-
Novel Triplet for Metastatic Esophageal Cancer: Study Results https://t.co/LaK7kC3Ip0 #esocsm #esophagealcancer #oncology
-
-
Mashup Score: 0Quality of Life With Nivolumab Plus Chemotherapy in Advanced Gastric/GEJ Cancer or Esophageal Adenocarcinoma - The ASCO Post - 7 month(s) ago
As reported in the Journal of Clinical Oncology, Markus Moehler, MD, and colleagues found that in the phase III CheckMate 649 trial, the addition of nivolumab to chemotherapy was associated with generally better patient-reported health-related quality of life outcomes in patients with advanced non–HER2-positive (HER2-negative or unknown HER2 status) gastric/gastroesophageal junction cancer or esophageal adenocarcinoma. The trial supported the April 2021 approval of nivolumab in combination with fluoropyrim
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Advanced Gastric and Esophageal Cancer: Quality of Life With Immunochemotherapy https://t.co/2sybdrJhwi #stcsm #esocsm #gastriccancer #esophagealcancer #GEJcancer #oncology #immunotherapy
-
-
Mashup Score: 0
Data from the NeoRes II trial caution against routinely delaying surgery for more than 6 weeks after patients with resectable locally advanced esophageal cancer receive neoadjuvant chemoradiotherapy.
Source: www.cancernetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data from the NeoRes II trial caution against routinely delaying surgery for more than 6 weeks after patients with resectable locally advanced esophageal cancer receive neoadjuvant chemoradiotherapy. #esocsm https://t.co/Grzmsdiu8x
-
-
Mashup Score: 0Addition of First-Line Regorafenib to Nivolumab and Chemotherapy in Metastatic Esophageal Cancer - The ASCO Post - 7 month(s) ago
In a single-institution phase II study reported in The Lancet Oncology, Cytryn et al found that the combination of regorafenib, nivolumab, and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) showed activity as a first-line treatment regimen for patients with HER2-negative metastatic esophagogastric adenocarcinoma. In the investigator-initiated trial, 39 patients enrolled between February 2021 and May 2022 at Memorial Sloan Kettering Cancer Center received FOLFOX (fluorouracil at 400 mg/m² bolus
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Addition of First-Line Regorafenib to Nivolumab and Chemotherapy in Metastatic Esophageal Cancer https://t.co/LaK7kC3azs #esocsm #esophagealcancer #oncology
-
-
Mashup Score: 15
Although underpowered and incomplete, Neo-AEGIS provides the largest comprehensive randomised dataset for patients with adenocarcinoma of the oesophagus and oesophagogastric junction treated with perioperative chemotherapy (predominantly the modified MAGIC regimen), and CROSS trimodality therapy, and reports similar 3-year survival and no major differences in operative and health-related quality of life outcomes. We suggest that these data support continued clinical equipoise.
Source: www.thelancet.comCategories: Gastroenterology, Latest HeadlinesTweet-
New research - Reynolds et al - Trimodality therapy vs perioperative chemotherapy for locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS phase 3 trial https://t.co/EdgLoCFAWw #OncTwitter #GITwitter #EsoCSM https://t.co/BN5X9IvM4A
-
-
Mashup Score: 8
PURPOSE There is limited evidence regarding the prognostic effects of pathological lymph node (LN) regression after neoadjuvant chemotherapy for esophageal adenocarcinoma, and a definition of LN response is lacking. This study aimed to evaluate how LN regression influences survival after surgery for esophageal adenocarcinoma. METHODS Multicenter cohort study of patients with esophageal adenocarcinoma treated with neoadjuvant chemotherapy followed by surgical resection at five high-volume centers in the United Kingdom. LNs retrieved at esophagectomy were examined for chemotherapy response and given a LN regression score (LNRS)—LNRS 1, complete response; 2, <10% residual tumor; 3, 10%-50% residual tumor; 4, >50% residual tumor; and 5, no response. Survival analysis was performed using Cox regression adjusting for confounders including primary tumor regression. The discriminatory ability of different LN response classifications to predict survival was evaluated using Akaike information cr
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
👍 Lymph node regression after neoadjuvant chemotherapy predicts survival in #EsophagealAdenocarcinoma ➡️ https://t.co/7qyN4q7xBb #esocsm @GSTTUGIresearch @adaviessurgeon
-
-
Mashup Score: 0Association of Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy With Outcomes in Esophageal Adenocarcinoma - The ASCO Post - 8 month(s) ago
In a UK study reported in the Journal of Clinical Oncology, Moore et al found that increased pathologic lymph node regression after neoadjuvant chemotherapy was associated with better outcomes in esophageal adenocarcinoma. The study involved patients treated with neoadjuvant chemotherapy followed by surgical resection at five high-volume UK centers between January 2000 and August 2020. 1 = complete response 2 = < 10% residual tumor 3 = 10% to 50% residual tumor 4 = > 50% residual tumor 5 = no response.
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Association of Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy With Outcomes in Esophageal Adenocarcinoma https://t.co/BmXKBTGnZt #esocsm #esophagealcancer #oncology
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 9 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📢That’s a wrap on the virtual #GDUGI2023! ➡️Checkout https://t.co/ys1d8pDAKO for highlights in GI oncology from the debates and updates from the meeting! ℹ️📽️ @GreatDebatesCME #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/DClUia5BdC
-
The endorsement for pembrolizumab plus chemotherapy in HER2-negative, locally advanced, unresectable, or metastatic gastric or GEJ adenocarcinomawas was based on overall survival findings from the phase 3 KEYNOTE-859 trial. #esocsm #oncology https://t.co/ujxaDfE0ia https://t.co/2Tra1EbI9z